In January, HHS released a proposed regulation that would "deregulate" 83 categories of devices currently reviewed by FDA. I heard it was released by HHS staff over the objection of the FDA staff.
But its comment period ran 60 days, and according to one news article, many of the comments were against the deregulation. (For example, devices that are not cleared and approved by FDA may not fall under some reimbursement rules.)
Supporters of the deregulation included Roche and Mayo, both in the context of telepathology or virtual pathology devices.
FDA has posted that, having reviewed the comments, it is withdrawing the proposal. See the inspection copy of the withdrawal, here. See a trade journal article on the withdrawal, here. See final publication, 86 FR 20174 (4pp), 4/16/2021, here.
The withdrawal is a bit harsh, accusing the Trump administration of having issued the January proposed rule with notice or approval of FDA, and being scientifically flawed and unsound. While they remark that the rule attracted many negative comments, they don't discuss the comments. Instead, they primarily withdraw the proposal due to finding it flawed and unsound.